Fibrinogen Degradation Products (FDP), Plasma
Under
normal conditions, the fibrinolytic process is localized on the fibrin clots
because alpha 2 -antiplasmin and the plasminogen activator inhibitors prevent
fibrinolysis from spreading. During disseminated intravascular coagulation
(DIC), fibrinolysis spreads and becomes systemic, in which case the degradation
of circulating fibrinogen will occur. Fragments that occur are very heterogeneous:
products derived from fibrin, soluble completes, degradation products from
fibrinogen, and from nonstabilized fibrin. An abnormal fibrinolytic and/or
fibrinogenolytic activity shown by high levels of FDP in plasma can also be
found in clinical states, such as eclampsia, carcinoma (promyelocytic leukemia),
postoperative complications, cardiac and renal disorders, hepatic disorders,
fibrinolysis, pulmonary embolism, and deep vein thrombosis (DVT). Positive
result indicates the presence of FDP at a concentration =2.5 mg/mL.
A significant
deviation from the normal range may require further evaluation by your physician.
Private MD Lab Services
offers the following test for Fibrinogen Degradation Products:
| Fibrinogen Degradation Products (FDP),
Plasma $47.99 |
Add To Cart |
| |
| |
